Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duvivier

Showing results (481-490 of 505) with videos related to

Pageof 51
Sort By:
European Radiology|April 19, 2024
Re-attendance in supplemental breast MRI screening rounds of the DENSE trial for women with extremely dense breastsStefanie G A Veenhuizen, Sophie E L van Grinsven, Isabelle L Laseur, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat'AIDS Cohort StudyMarie Demontès, Sabrina Eymard Duvernay, Clotilde Allavena, et al.
Annales D'Endocrinologie|July 4, 2012
How to diagnose a lipodystrophy syndromeMarie-Christine Vantyghem, Anne-Sophie Balavoine, Claire Douillard, et al.
Clinical Radiology|May 16, 2018
Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breastsS V de Lange, M F Bakker, E M Monninkhof, et al.
JCO Precision Oncology|December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyNitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTimothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Journal of Hepatology|February 26, 2017
Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohortLionel Piroth, Linda Wittkop, Karine Lacombe, et al.
HIV Medicine|June 27, 2020
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatmentA Mocroft, B Neesgard, R Zangerle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Pageof 51

Showing results (481-490 of 505) with videos related to

Sort By:
Pageof 51
European Radiology|April 19, 2024
Re-attendance in supplemental breast MRI screening rounds of the DENSE trial for women with extremely dense breastsStefanie G A Veenhuizen, Sophie E L van Grinsven, Isabelle L Laseur, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Multimorbidity in Elderly Persons According to the Year of Diagnosis of Human Immunodeficiency Virus Infection: A Cross-sectional Dat'AIDS Cohort StudyMarie Demontès, Sabrina Eymard Duvernay, Clotilde Allavena, et al.
Annales D'Endocrinologie|July 4, 2012
How to diagnose a lipodystrophy syndromeMarie-Christine Vantyghem, Anne-Sophie Balavoine, Claire Douillard, et al.
Clinical Radiology|May 16, 2018
Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breastsS V de Lange, M F Bakker, E M Monninkhof, et al.
JCO Precision Oncology|December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyNitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTimothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Journal of Hepatology|February 26, 2017
Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohortLionel Piroth, Linda Wittkop, Karine Lacombe, et al.
HIV Medicine|June 27, 2020
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatmentA Mocroft, B Neesgard, R Zangerle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyHerbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Pageof 51